A biotech stock can double before lunch and crash by dinner because most of these companies don’t sell anything yet. Their drug is still stuck in trials, so there’s no real revenue coming in. The entire stock price is a bet on one question. Will this drug get approved someday?
An FDA approval letter means yes, the drug can finally be sold, so the stock jumps because a real business just showed up. A rejection letter, often called a Complete Response Letter, means no, or that the company needs more data, more years, and more cash.
The stock craters because the “someday” story just got a lot less believable. Ignore that pattern, and the market runs you over. Learn to read it, and you’re the one still standing when the dust settles.
Most of those traders never learn what actually drives the move, and that’s exactly what this guide covers.
Table of Contents
Biotech Stocks Play by Different Rules
Small biotech companies burn cash faster than they earn it. Most don’t sell a single product yet. Their whole value sits on what happens in a lab, a trial, or a regulator’s inbox next month.
That setup creates wild price swings. A single headline can send a $2 stock to $6 in a single session. The same headline, phrased differently, can wipe out half its value. Here, you’re betting on outcomes that haven’t happened yet.
Compare that to a company selling something people already buy every week. Its stock moves on quarterly earnings and not much else.
A biotech stock doesn’t wait for a quarterly report. It moves the second a lab result or a regulatory letter lands, and that can happen on a random Tuesday afternoon with zero warning.
Three Things That Actually Move the Price
Retail traders spot this late almost every time, days or weeks after the filing actually posted. By the time it shows up on a stock forum, half the move already happened. Check filings directly on the SEC’s EDGAR database instead of waiting for someone else to point it out to you.
Here are things to look out for:
- FDA Decisions: Approval dates are public, and they’re the single biggest catalyst in this space. A green light can triple a stock overnight. A rejection letter, often called a Complete Response Letter, can cut it in half by the opening bell.
- Trial Data: Phase 2 and Phase 3 readouts carry the same weight. Strong data validates the drug and pulls in new buyers fast. Weak data does the opposite, and it does it immediately. The reaction happens in minutes.
- Institutional Buying: When a big fund quietly builds a stake in a microcap biotech, that’s worth noticing. Firms like that don’t usually gamble on a hunch. A 13D or 13G filing showing a serious position is a signal that someone did homework you haven’t seen yet.
How to Build a Watchlist That Actually Earns Its Spot
Most people don’t build a real biotech stock watchlist. They just keep opening the same five stocks in their brokerage app out of habit. That’s not tracking anything. That’s just staring.
A real watchlist tracks upcoming events, not just tickers. Trader and educator Tim Sykes keeps a running biotech stock watchlist that he rebuilds every month based on which companies have a real catalyst on the calendar, not just hype. A stock without a near-term event is just a stock sitting there.
What Belongs on the List
Put the float on there first. A company with 5 million shares outstanding moves a lot harder on the same volume than one with 200 million.
Add the next catalyst date, whether that’s an FDA decision, a trial readout, or an earnings call where management might drop new guidance.
Add cash on hand and burn rate too, since a company running low on money almost always needs to raise more, and that usually means diluting existing shareholders.
Skip the stocks with no near-term event. A cheap biotech share with nothing scheduled for six months is just dead money sitting in your account.
Your watchlist should read like a calendar with tickers attached to it, not a random pile of names you liked once.
Where the Catalysts Actually Hide
FDA decision dates sit on the company’s own investor relations page, usually buried in an old press release. ClinicalTrials.gov lists expected data readout windows for anyone willing to dig. SEC filings, specifically 8-Ks and 10-Qs, spell out cash burn in exact numbers.
None of these need special access, and accessing these only takes fifteen minutes of your time.
The Real Risk Is Dilution
FDA rejection gets all the attention, but dilution quietly does more damage to more traders. When a small biotech’s stock spikes on good news, management often turns around and sells a pile of new shares while the price is high. That’s smart for the company’s balance sheet and brutal for anyone who bought in expecting the run to keep going.
The SEC defines a penny stock as one trading under $5 a share, and biotech names live in that price range constantly for exactly this reason. Shares get printed, float grows, and price gets pulled back down even when the underlying science hasn’t changed at all.
If you only watch for bad trial results, you’ll miss the thing that actually erodes your position more often.
I’d rather trade a stock with a nasty dilution history I understand than one with clean data and zero cash left in the bank.
Read the last 10-Q before you read the press release. The press release is written to excite you. The financial statement just tells you the truth.
Track the Calendar, Not the Chart
The chart tells you what already happened. The catalyst calendar tells you what’s coming. Anyone serious about trading this sector checks FDA decision dates and trial readouts before they check the ticker’s daily move.
None of this makes biotech safe. It’s still one of the most volatile corners of the market, and plenty of these companies won’t exist in five years. But a trader who tracks the calendar walks into a trade knowing why the stock might move.
A trader who doesn’t is just along for whatever ride the headlines decide to give them. Build the habit now, because the next binary event in this space is never more than a few weeks away.
